Zimmer Biomet creates independent non-profit organization to reduce health disparities

Zimmer Biomet this week announced it created an independent 501(c)(3) for its philanthropic, multi-disciplinary coalition Movement is Life.

The new 501(c)(3) non-profit organization designation will allow the Warsaw, Indiana-based company to raise awareness of the impact of disparities on chronic disease management and quality of life among women, racial and ethnic minorities and women living in rural communities.

“We’re excited to take this next step in the evolution of Movement is Life as we continue on our path to address disparities in underserved communities and populations,” said Dr. Mary O’Connor, co-founder, chief medical officer and chief compliance officer at Vori Health, and chair of the Movement is Life board of directors. “The inaugural Movement is Life board of directors shares my gratitude to Zimmer Biomet for their incredible support in our growth. We are excited and eager to work together as an independent organiza…

Read more
  • 0

Needham & Co. downgrades Medtronic, Zimmer Biomet shares

[Image from Unsplash]Needham & Co. senior research analyst Mike Matson today downgraded his rating of Medtronic (NYSE: MDT) and Zimmer Biomet (NYSE: ZBH) shares to Hold, while Boston Scientific (NYSE:BSX) got an upgrade to Buy.

MDT shares were down more than 1% to $97.98 apiece in morning trading, a day after Q4 earnings that missed The Street sent the medtech giant’s stock down more than 5%. ZBH shares were down slightly at $119.87 apiece, while BSX shares were up more than 2% at $41.15 apiece. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 1%.

When it came to Medtronic, Matson said: “The more things change, the more they stay the same.”

“MDT seems to have returned to its old pattern of poor execution and inconsistent results, and this is its third strike in our view, with the first being pipeline challenges (RDN and robotics) and the second bei…

Read more
  • 0

Zimmer Biomet adds ESG and CEO visibility to executive’s duties

Zimmer Biomet Chief Communications and Administration Officer Keri Mattox [Photo courtesy of Zimmer Biomet]Zimmer Biomet (NYSE:ZBH) today announced additional responsibilities for Investor Relations SVP and Chief Communications Officer Keri Mattox.

Mattox’s new title at the Warsaw, Indiana-based orthopedics company is chief communications and administration officer.

She will be responsible for “building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CEO visibility, engagement and accessibility,” the company said in a news release.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Zimmer Biomet narrowly avoids shareholder rebuke on executive pay

Zimmer Biomet CEO Bryan Hanson [Photo courtesy Zimmer Biomet]An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting.

About 54 percent of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday.

In 2021, nearly 93 percent of voting shareholders supported the executive compensation plan in what’s known as the Say on Pay vote, the company said in an SEC filing.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Zimmer Biomet appoints new chief accounting officer

Zimmer Biomet (NYSE: ZBH) today announced that it appointed Paul Stellato as VP, controller and chief accounting officer.

Prior to joining the Warsaw, Indiana-based company, Stellato was VP of finance and global business services at Xylem inc. He has also held numerous leadership roles at ITT Corporation, Arthur Andersen and Ernst & Young.

“With more than two decades of experience and a demonstrated track record of success in all areas of financial services, Paul will be a great addition to our leadership team in his new role,” said CFO Suky Upadhyay. “His experience and expertise in key finance areas including controllership, FP&A, investor relations and internal audit will be extremely valuable as we continue to drive our business forward.”

Read more
  • 0

Zimmer Biomet introducing AI for its for Omni Suite intelligent operating room

Zimmer Biomet (NYSE: ZBH) this week launched its artificial intelligence (AI) capabilities within its Omni Suite intelligent operating room.

The Warsaw, Indiana-based company designed the intelligent OR to optimize surgical workflow and procedural efficiency by automating manual tasks. The newly-released AI feature uses cameras to automatically recognize and timestamp key OR workflow milestones, including patient entry and exit, door count, anesthesia administration, surgery and cleaning.

“Omni Suite is more than just another manual integration solution – it is a smart system designed to work with OR staff throughout the procedure,” Robert Kraal, VP and GM of connected health at Zimmer Biomet, said in a news release. “Now, with this new feature, surgical teams can utilize and rely on Omni Suite’s AI capabilities to optimize OR workflow. By providing data points that have been historically captured manually, if at all, surgical teams can …

Read more
  • 0

Thanks, mom! Medtech leaders reflect on Mother’s Day

[Photo from Aditya Romansa on Unsplash]Everyone has a story about how they got into medtech, and it’s no surprise that many of those stories start with how we were raised.

As Mother’s Day approaches, Medical Design & Outsourcing asked medtech leaders to share some thoughts about how their moms inspired their careers, the products they make and the companies they’ve built.

We can never say “thanks” often enough to truly show our gratitude – but one more time can’t hurt.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Zimmer Biomet rises on Street-beating Q1, raised guidance

Zimmer Biomet (NYSE:ZBH) shares ticked up this morning on first-quarter results that came in ahead of the consensus forecast.

The Warsaw, Indiana-based company posted profits of $14.2 million, or 7¢ per share, on sales of $1.7 billion for the three months ended March 31, 2022, for a 92.8% bottom-line slide on sales growth of 3.9%.

Adjusted to exclude one-time items, earnings per share were $1.61, 20¢ ahead of Wall Street, where analysts were looking for sales of $1.6 billion.

Zimmer Biomet also completed the previously announced spinoff of ZimVie — its former dental and spine businesses.

“We are encouraged by the better than expected results seen in Q1, driven by COVID recovery and continued execution by the Zimmer Biomet team. This performance increases our confidence level for 2022 and we are raising and tightening our guidance accordingly,” Zimmer Biomet Chair, President and CEO Bryan Hanson said in a news release. “Our underlying business rema…

Read more
  • 0

ZimVie ticks up on 2021 revenue beat, reaffirms 2022 guidance

ZimVie (NASDAQ:ZIMV) shares rose slightly this morning on full-year 2021 revenues that came in ahead of the consensus forecast.

Full-year revenues for the company topped $1 billion, beating Wall Street projections by more than $20 million.

The new Zimmer Biomet (NYSE:ZBH) spinoff of its spine and dental businesses posted fourth-quarter losses of $60.7 million on sales of $261.6 million for the three months ended Dec. 31, 2021. ZimVie successfully completed its spinoff from Zimmer Biomet last month.

READ: CEO Vafa Jamali has big plans for ZB spinoff ZimVie — but it’ll take time

Losses were impacted by a $40.3 million brand rationalization charge in 2021, according to a news release. That charge was related to products the company intends to discontinue, as well as a resumption of spending in 2021 that had been reduced in 2020 due to the COVID-19 pandemic.

“We are intently focused on strengthening our foundation in…

Read more
  • 0

Zimmer Biomet debuts AI to predict post-operative recovery

When used over an iPhone, WalkAI can notify health professionals about predicted outcomes through the MyMobility clinician dashboard. [Image courtesy of ZB. Patients are fictitious.]Zimmer Biomet (NYSE and SIX: ZBH) today launched WalkAI, artificial intelligence that can predict which patients will have lower gait speed 90 days after hip or knee surgery.

WalkAI is part of ZBEdge, Zimmer Biomet’s suite of integrated smart, digital and robotic technologies to boost patient outcomes after orthopedic surgeries.

The proprietary algorithm behind WalkAI analyzes a person’s mobility to generate a personalized daily prediction of their gait (walking) speed at 90 days after surgery. The daily predictions draw on extensive, anonymized, real-world data in the ZBEdge database.

“WalkAI is built from our wealth of anonymized ZBEdge data and is the first model to demonstrate our unique capability to deliver actionable predictions by connecting real-world …

Read more
  • 0

Vafa Jamali has big plans for ZB spinoff ZimVie — but it’ll take time

ZimVie CEO Vafa Jamali [Image courtesy of Jamali]ZimVie CEO Vafa Jamali sees opportunities for growth in the spine space, including pediatric devices.

The efforts, though, will take years for ZimVie (NASDAQ:ZIMV), the new Zimmer Biomet (NYSE:ZBH) spinoff of its spine and dental businesses.

That was the big takeaway when MassDevice and Medical Design & Outsourcing caught up with Jamali today, shortly after he rang in the Nasdaq on the first day of trading for ZIMV shares. (Listen to the full interview during our upcoming DeviceTalks Weekly podcast.)

Over the past decade, Jamali rose through the ranks at Covidien and then Medtronic after the $50 billion merger of the two companies in 2015. His focus over the years was growing business in the gastroenterological diseases space.

Now Jamali has the chance to do it again in the spine and dental area — except he can run it all from the corner office.

“The responsibility is yours and the decision-…

Read more
  • 0

Zimmer Biomet completes ZimVie spinoff

Zimmer Biomet (NYSE:ZBH) announced today that it completed the spinoff of ZimVie, its former dental and spine businesses.

Shares of ZimVie will begin trading on the Nasdaq market today under the “ZIMV” ticker.

Warsaw, Indiana-based Zimmer Biomet previously announced the spinoff of its spine and dental businesses in February 2021. In that same month, Zimmer Biomet said Vafa Jamali will serve as the CEO of the spinoff.

Last month, when announcing its fourth-quarter earnings, Zimmer Biomet confirmed the planned completion date for the ZimVie spinoff was March 1, 2022.

“The spinoff of ZimVie marks a major milestone in the active portfolio management of Zimmer Biomet as we continue to strengthen our position as a global leader in the medtech space,” Zimmer Biomet Chairman, President and CEO Bryan Hanson said in a news release.  “We are confident that this transaction will create shareholder value for both companies and wil…

Read more
  • 0